Roman E. Izrailov

Roman E. Izrailov

Auto-generated profile, based on publicly available information

Roman E. Izrailov

Loginov Moscow Clinical Scientific Center

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
RIRoman E. Izrailov
Roman E. Izrailov
NSNikolay E. Semenov
Nikolay E. Semenov
LZLiudmila Zhukova
Liudmila Zhukova
PFPolina S. Feoktistova
Polina S. Feoktistova
DMDanila A. Matveychuk
Danila A. Matveychuk
IKIgor E. Khatkov
Igor E. Khatkov
Background. To date, there is no consensus on the preferred sequence of combined treatment in patients with locally advanced gastric cancer (perioperative chemotherapy – POCT or primary surgical treatment). No direct comparison of these approaches had been conducted before. Aim. To compare, in retrospective analysis, 3-year relapse-free (RFS) and overall survival (OS) in patients receiving POCT FLOT or adjuvant chemotherapy XELOX/FOLFOX for locally advanced gastric cancer. Materials and methods. The assessment included 153 patients who underwent POCT FLOT and 171 patients who underwent surgical treatment at the first stage. When evaluating the initial characteristics, it was shown that patients with ECOG (The Eastern Cooperative Oncology Group) stage 1-2, clinical stage cT4a-b, cN2-3 and Bormann type 4 to were significantly more common in the POCT group. Morphological characteristics: grade, presence of signet cell carcinoma, HER2/neu overexpression, microsatellite instability, sensitivity to immunotherapy (Combined Positive Score) didn't differ. Results. With a median follow-up of 40 months, it was shown that the long-term results assessed in all included patients were better in the group with primary surgical treatment: 3-year RFS was 55 and 40% (risk ratio – RR 1.33, 95% confidence interval – CI 1.08–1.64; р=0.007). 3-year OS was 68 and 56% (RR 1.36, 95% CI 1.02–1.8; р=0.04), respectively. However, when evaluating patients who received surgical treatment in the POCT group (n=121, 79%), the results did not differ: 3-year RFS 55 and 50% (RR 0.9, 95% CI 0.71–1.16; р=0.97), 3-year OS 68 and 63% (RR 1.1, 95% CI 0.84–1.59; р=0.97). Insufficient volume of adjuvant chemotherapy (75% of the dose) significantly worsened long-term results (3-year OS 43 and 71%; p=0.002). Conclusion. The obtained data of a retrospective analysis did not reveal the advantages of any of the approaches provided that the surgical stage was performed in patients receiving POCT. To obtain more objective results, it is necessary to conduct randomized multicenter studies in the high volume centers, providing the necessary sample capacity, quality of diagnosis and treatment. Thus, the design of future studies should be based on the hypothesis of non-inferiority, which inevitably entails a significant increase in the required number of observations to obtain reliable sampling power.

22 September 2019 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Closed access
IKI. E. Khatkov
I. E. Khatkov
VTV. V. Tsvirkun
V. V. Tsvirkun
RIR. E. Izrailov
R. E. Izrailov
MMM. V. Mikhnevich
M. V. Mikhnevich
OVO. S. Vasnev
O. S. Vasnev
AVA. N. Vankovich
A. N. Vankovich
Objective. To assess the role of minimally invasive surgery for periampullary cancer.Material and methods. A systematic literature review of original articles devoted to comparison of open, laparoscopic and robot-assisted pancreatoduodenectomy was performed. Also, our own experience of minimally invasive pancreatoduodenectomy is shown.Results. Articles included in the analysis showed comparable results of minimally invasive and open pancreatoduodenectomy regarding morbidity, mortality and oncological outcomes. Laparoscopic and robot-assisted pancreatoduodenectomy are associated with significantly less intraoperative blood loss and length of postoperative hospital-stay. However, these procedures require more time.Conclusion. Minimally invasive surgery does not worsen perioperative outcomes and may be considered as an alternative to open procedures in selective patients. Minimally invasive techniques should be implemented in highvolume pancreatic centers only with specialists experienced in minimally invasive surgery.

22 September 2025 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Open access
PDF file
IKI. E. Khatkov
I. E. Khatkov
VTV. V. Tsvirkun
V. V. Tsvirkun
PTP. S. Tyutyunnik
P. S. Tyutyunnik
AAA. R.O. Aliev
A. R.O. Aliev
SAS. M. Akhmadzoda
S. M. Akhmadzoda
ASA. V. Shabunin
A. V. Shabunin
In 2023, with the approval of the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, a consensus study was initiated and conducted on the diagnosis, management, and follow-up of patients with serous and mucinous neoplasms of the pancreas. Based on an extensive literature review, responses to each of the 22 questions posed were formulated and compiled into a Consensus Document. A total of 44 experts representing 27 institutions across 9 countries participated in the preparation of the Consensus. The Delphi method was employed for voting, and ultimately, including the results of votes on selected statements during the final conference, consensus was achieved on all questions.

10 August 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
IKIgor E. Khatkov
Igor E. Khatkov
NSNikolai N. Semenov
Nikolai N. Semenov
RIRoman E. Izrailov
Roman E. Izrailov
MEMikhail Efanov
Mikhail Efanov
KDKamil D. Dalgatov
Kamil D. Dalgatov
LZLiudmila Zhukova
Liudmila Zhukova
Background. Currently available data on the efficacy and indications for neoadjuvant chemotherapy in patients with primary resectable pancreatic cancer are contradictory and not clearly defined. Aim. To conduct a comparative assessment of the effectiveness of neoadjuvant chemotherapy and primary surgical treatment followed by adjuvant chemotherapy in patients with primary resectable pancreatic cancer. Materials and methods. In our study, the efficacy of neoadjuvant chemotherapy was retrospectively evaluated in 45 patients and in 153 patients with primary surgical treatment and subsequent adjuvant chemotherapy. Results. With a median follow-up of 41.7 months. Both, recurrence free survival in the group of patients receiving neoadjuvant chemotherapy followed by surgical treatment (n=33; 73%) and in the group with surgical treatment and subsequent adjuvant chemotherapy (13.9 and 19.5 months; p=0.35) and overall survival (28.4 months vs 33.7 months; p=0.29) were no different. The CA level of 19.9500 IU/ml in the neoadjuvant chemotherapy group was observed in 20 (44.4%) patients. At the same time, surgical treatment was performed only in 11 (55%) patients. At the same time, at the CA 19.9 level 500 IU/ml, at the end of neoadjuvant chemotherapy, surgical treatment was not performed in only 3 (12%) patients (p=0.005). Conclusion. The long-term results of treatment of patients with primary resectable pancreatic cancer, whose first stage was neoadjuvant chemotherapy, practically do not differ from the group whose treatment began with surgery. Treatment of patients with an initially high (500 IU/ml) level of CA 19.9 is preferable to start with neoadjuvant chemotherapy. Patients who may have doubts about the likelihood of adjuvant chemotherapy (general condition, social adaptation, place of residence), it is also preferable to start treatment with neoadjuvant chemotherapy. It is necessary to change the algorithm of examination of patients, especially those with a level of CA 19.9500 IU/ml, to exclude a greater prevalence, for example, performing diagnostic laparoscopy to exclude metastases in the peritoneum.

15 March 2024 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Open access
PDF file
LZLiudmila Zhukova
Liudmila Zhukova
RIR. E. Izrailov
R. E. Izrailov
NSN. N. Semenov
N. N. Semenov
MMM. V. Mikhnevich
M. V. Mikhnevich
IKI. E. Khatkov
I. E. Khatkov
   Aim. To evaluate long-term oncological outcomes of pancreatoduodenectomy in resectable pancreatic head cancer in patients over 70 years of age.   Materials and methods. A retrospective analysis of the Moscow Clinical Scientific Center registry revealed 63 patients aged > 70 years with resectable pancreatic head cancer. In 2016–2023, these patients underwent pancreatoduodenectomy. Males accounted for 35 %, and the median age comprised 75 years. Stage II was diagnosed in 44.4 % of patients, stage I – in 31.7 %, and stage III – in 23.8 %. Median follow-up accounted for 34.5 months. The authors analyzed the effect of patient characteristics, tumor, perioperative data and method of surgery on overall survival.   Results. Adjuvant chemotherapy (p = 0.005; HR 0.28, CI 0.115–0.62) and low preoperative albumin levels (p = 0.004; HR 0.203, CI 0.28–0.61) had a significant impact on overall survival. After open surgery, 56 % of patients did not receive adjuvant chemotherapy, after minimally invasive surgery – 15.4 % (p = 0.0001).   Conclusion. Minimally invasive pancreatoduodenectomy reveals no negative effect on the oncological outcomes of treatment for resectable pancreatic head cancer in patients ≥ 70 years old. Adjuvant chemotherapy and hypoalbuminemia prior to surgery are considered to be statistically significant factors influencing overall survival. Minimally invasive techniques enable adjuvant chemotherapy to be administered to a larger number of patients compared to open intervention.

14 September 2026 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
ARA.B. Ryabov
A.B. Ryabov
NAN.M. Abdulkhakimov
N.M. Abdulkhakimov
VAV.G. Agadzhanov
V.G. Agadzhanov
MAM.V. Agasiev
M.V. Agasiev
AAA.E. Anisimov
A.E. Anisimov
DSD.D. Sekhniaidze
D.D. Sekhniaidze
Objective. To evaluate 90-day morbidity and mortality rates after elective radical surgery for esophageal and esophagogastric junction cancer within the prospective multiple-center study ESOSTAT. Material and methods. The study included 230 patients from 18 oncology hospitals in the Russian Federation and the Republic of Belarus who underwent elective radical esophagectomy for primary esophageal cancer or esophagogastric junction cancer (Siewert I–II) between March 18 and September 18, 2024. Complications were uniformly recorded using the ESODATA system with severity graded according to the Clavien-Dindo classification. Univariate and multivariate logistic regression analyses were performed to identify risk factors of postoperative complications and mortality. Results. The 90-day mortality rate was 8.7%, in-hospital mortality — 4.8%. The overall complication rate was 41.3%, including surgical complications in 26.5% of patients and redo surgeries in 17.4% of cases. The most common complications were pulmonary (22.1%) and anastomotic leakage (11.3%). The mortality rate associated with anastomotic leakage was 19.2%. Multivariate analysis identified female sex (OR=0.732; 95% CI 0.548–0.978; p=0.035), ECOG status 2 (OR=10.142; 95% CI 1.575–65.366; p=0.015), surgery time (OR=1.003; 95% CI 1.001–1.005; p=0.006), and intraoperative blood loss (OR=1.001; 95% CI 1.000–1.002; p=0.027) as independent predictors of complications. Factors independently associated with 90-day mortality were Charlson comorbidity index >4 (OR=1.260; 95% CI 1.062–1.495; p=0.008), complicated course of esophageal cancer (OR=1.560; 95% CI 0.637–2.305; p=0.025), concomitant pulmonary diseases (OR=3.328; 95% CI 1.083–10.227; p=0.036), and any postoperative complication (OR=36.554; 95% CI 15.800–84.521; p<0.001). Conclusion. The ESOSTAT study is the first in Russia and Belarus to evaluate 90-day morbidity and mortality rates after esophagectomy. Our findings are comparable with international registries, support 90-day follow-up period and identify key prognostic factors. Risk factor analysis will allow patient stratification according to the likelihood of adverse outcomes, facilitate more rigorous patient selection, and ultimately improve safety of surgical treatment.